Back to top
more

CureVac (CVAC)

(Real Time Quote from BATS)

$2.34 USD

2.34
101,109

+0.03 (1.30%)

Updated Apr 26, 2024 10:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

by Zacks Equity Research

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

by Zacks Equity Research

The heavy selling pressure might have exhausted for CureVac N.V. (CVAC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Company News for Jan 11, 2023

by Zacks Equity Research

Companies In The News Are: SNX, ACI, MSFT, CVAC.

Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ekta Bagri headshot

Bet on These 4 Biotech Stocks With Bright Prospects

by Ekta Bagri

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks

by Zacks Equity Research

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants

by Zacks Equity Research

Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.

Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

by Zacks Equity Research

GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.

Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.

Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

by Zacks Equity Research

The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).

CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study

by Zacks Equity Research

CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.

CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data

by Zacks Equity Research

CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

by Zacks Equity Research

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

by Zacks Equity Research

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

by Zacks Equity Research

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response

by Zacks Equity Research

Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.

Neena Mishra headshot

Best Biotech Stocks & ETFs for mRNA, Gene Editing

by Neena Mishra

Here is what you should know about investing in these life changing technologies.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

by Zacks Equity Research

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

by Zacks Equity Research

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.